BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25634007)

  • 1. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer.
    Park HS; Harder EM; Mancini BR; Decker RH
    J Thorac Oncol; 2015 May; 10(5):832-837. PubMed ID: 25634007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic body radiotherapy for central lung tumors.
    Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
    J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
    Parker SM; Siochi RA; Wen S; Mattes MD
    Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
    Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
    Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
    Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.
    Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB
    Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.
    Nguyen KNB; Hause DJ; Novak J; Monjazeb AM; Daly ME
    Pract Radiat Oncol; 2019 Mar; 9(2):e196-e202. PubMed ID: 30496842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage stereotactic body radiation therapy (SBRT) for local failure after primary lung SBRT.
    Hearn JW; Videtic GM; Djemil T; Stephans KL
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):402-6. PubMed ID: 25017480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer.
    Videtic GM; Stephans KL; Woody NM; Reddy CA; Zhuang T; Magnelli A; Djemil T
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):203-8. PubMed ID: 25015198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
    Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.
    Fakiris AJ; McGarry RC; Yiannoutsos CT; Papiez L; Williams M; Henderson MA; Timmerman R
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):677-82. PubMed ID: 19251380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
    Meng MB; Wang HH; Zaorsky NG; Sun BS; Zhu L; Song YC; Li FT; Dong Y; Wang JS; Chen HM; Yu XY; Yuan ZY
    Cancer Sci; 2019 Nov; 110(11):3553-3564. PubMed ID: 31464032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience.
    Raman S; Yau V; Pineda S; Le LW; Lau A; Bezjak A; Cho BCJ; Sun A; Hope AJ; Giuliani M
    Clin Lung Cancer; 2018 Sep; 19(5):e803-e810. PubMed ID: 30007498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
    Mangona VS; Aneese AM; Marina O; Hymas RV; Ionascu D; Robertson JM; Gallardo LJ; Grills IS
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):124-32. PubMed ID: 25442337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.